Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.

BMJ Open Diabetes Res Care · 2021 · PMC7818813 · PMID 33472796

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Since there was a highly significant difference in mortality favoring SGLT2i ‘add-on’ treatment, NNT was calculated ( online supplemental table 8 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.